Literature DB >> 22099240

Influenza A (H1N1) 2009 monovalent vaccination among adults with asthma, U.S., 2010.

Peng-jun Lu1, David B Callahan, Helen Ding, Gary L Euler.   

Abstract

BACKGROUND: The 2009 pandemic influenza A (H1N1) virus (2009 H1N1) was first identified in April 2009 and quickly spread around the world. The first doses of influenza A (H1N1) 2009 monovalent vaccine (2009 H1N1 vaccine) became available in the U.S. in early October 2009. Because people with asthma are at increased risk of complications from influenza, people with asthma were included among the initial prioritized groups.
PURPOSE: To evaluate 2009 H1N1 vaccination coverage and identify factors independently associated with vaccination among adults with asthma in the U.S.
METHODS: Data from the 2009-2010 BRFSS (Behavioral Risk Factor Surveillance System) influenza supplemental survey were used; responses from March through June 2010 were analyzed to estimate vaccination levels of 2009 H1N1 vaccine among respondents aged 25-64 years with asthma. Multivariable logistic regression and predictive marginal models were performed to identify factors independently associated with vaccination.
RESULTS: Among adults aged 25-64 years with asthma, 25.5% (95% CI=23.9%, 27.2%) received the 2009 H1N1 vaccination. Vaccination coverage ranged from 9.9% (95% CI=6.4%, 15.1%) in Mississippi to 46.1% (95% CI=33.3%, 61.2%) in Maine. Characteristics independently associated with an increased likelihood of vaccination among adults with asthma were as follows: had a primary doctor, had other high-risk conditions, and received seasonal influenza vaccination in the 2009-2010 season.
CONCLUSIONS: Vaccination coverage among adults aged 25-64 years with asthma was only 25.5% and varied widely by state and demographic characteristics. National and state-specific 2009 H1N1 vaccination coverage data for adults with asthma are useful for evaluating the vaccination campaign and for planning and implementing strategies for increasing vaccination coverage in possible future pandemics. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22099240     DOI: 10.1016/j.amepre.2011.08.004

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  7 in total

1.  First things first: protecting children with asthma from infection with influenza.

Authors:  Paul L Garbe; David B Callahan; Peng-Jun Lu; Gary L Euler
Journal:  Am J Respir Crit Care Med       Date:  2012-06-15       Impact factor: 21.405

2.  Influenza vaccination among persons with work-related asthma.

Authors:  Jacek M Mazurek; Gretchen E White; Jeanne E Moorman; Eileen Storey
Journal:  Am J Prev Med       Date:  2014-06-18       Impact factor: 5.043

Review 3.  Infection in severe asthma exacerbations and critical asthma syndrome.

Authors:  Christian E Sandrock; Andrew Norris
Journal:  Clin Rev Allergy Immunol       Date:  2015-02       Impact factor: 8.667

4.  Influenza A (H1N1) 2009 monovalent and seasonal influenza vaccination among adults 25 to 64 years of age with high-risk conditions--United States, 2010.

Authors:  Peng-jun Lu; Amparo Gonzalez-Feliciano; Helen Ding; Leah N Bryan; David Yankey; Elizabeth A Monsell; Stacie M Greby; Gary L Euler
Journal:  Am J Infect Control       Date:  2013-02-15       Impact factor: 2.918

5.  Seasonal influenza vaccination coverage among adult populations in the United States, 2005-2011.

Authors:  Peng-Jun Lu; James A Singleton; Gary L Euler; Walter W Williams; Carolyn B Bridges
Journal:  Am J Epidemiol       Date:  2013-09-05       Impact factor: 4.897

6.  National and State-Specific Td and Tdap Vaccination of Adult Populations.

Authors:  Peng-Jun Lu; Alissa O'Halloran; Helen Ding; Jennifer L Liang; Walter W Williams
Journal:  Am J Prev Med       Date:  2015-11-29       Impact factor: 5.043

7.  Determinants of healthcare provider recommendations for influenza vaccinations.

Authors:  Reginald Villacorta; Neeraj Sood
Journal:  Prev Med Rep       Date:  2015-04-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.